Xcovery to Present at 25th Annual Florida Venture Capital Conference

Jan 26, 2016, 18:11 ET from Xcovery

PALM BEACH GARDENS, Fla., and NEEDHAM, Mass., Jan. 26, 2016 /PRNewswire/ -- Xcovery, a developer of targeted therapeutics for cancer, today announced it will present a company update during the 25th annual Florida Venture Capital Conference at the Vinoy Renaissance Resort & Golf Club in St. Petersburg.

Xcovery CEO Michael D. Webb will present a company update on Jan. 29, 2016.

Xcovery's lead asset is X-396, a small molecule, anaplastic lymphoma kinase (ALK) inhibitor. It is being studied in the Xalt2 Study, a phase 2 trial for the treatment of ALK-positive non-small cell lung cancer (NSCLC). X-396 also is being studied to treat patients with lymphoma and neuroblastoma. X-396 has been validated in potency and selectivity assays that demonstrate it is more selective and up to 10 times more potent than competitive ALK inhibitors tested. The Xalt2 Study is currently enrolling patients. To learn more, visit: www.xalt2study.com.

Florida Venture Capital Conference is connecting Florida Entrepreneurs and Capital Sources to assist in obtaining funding through education, strategic partnering and effective networking. The Florida Venture Capital Conference offers numerous networking opportunities, programming, featuring top investors and deal makers active in the state, and showcases Florida's most innovative and fast growing later stage, private companies before an audience of venture capitalists and other investors.

About Non-Small Cell Lung Cancer and ALK
Lung cancer is the second most common type of cancer identified in the United States with an estimated 221,000 new diagnoses expected in 2015.  Non-small cell lung cancer is the most common type of lung cancer, accounting for an estimated 85-90% of the lung cancer cases.

The anaplastic lymphoma kinase (ALK) gene is located on chromosome 2 and rearrangement of the ALK gene can lead to its activation or expression therefore increasing a person's chance of certain types of cancer, including NSCLC.  Between three and seven percent of patients with NSCLC have the ALK rearrangement making this a molecular target warranting investigation for NSCLC patients.

About Xcovery
Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors.  Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors.  For more information, visit www.xcovery.com

Forward-Looking Statements
This press release contains forward-looking statements that are based on company management's current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.

Corporate Contact:
Teri Swift
Xcovery Corporate Communications
(561) 727-9559

Logo - http://photos.prnewswire.com/prnh/20151228/318197LOGO

SOURCE Xcovery